Tesamorelin and AOD 9604 are different peptides: tesamorelin is FDA-approved for HIV lipodystrophy, while AOD 9604 remains research-only for human use.
Tesamorelin and AOD 9604 are two different peptides that are often mentioned together because both are studied for fat loss, but they are not interchangeable. Tesamorelin is an FDA-approved growth hormone-releasing hormone (GHRH) analog prescribed for excess abdominal fat in adults with HIV-associated lipodystrophy, while AOD 9604 is a synthetic fragment of human growth hormone that has never been approved by the FDA for human use. Anyone comparing aod 9604 vs tesamorelin should start with that single fact, because it shapes everything else about dosing, safety, and legal access.
What Is Tesamorelin?
Tesamorelin is a 44-amino-acid GHRH analog sold under the brand name Egrifta. It works upstream by signaling the pituitary gland to release the body's own growth hormone, which raises IGF-1 levels and increases lipolysis, especially in visceral fat.
It is the only peptide in this pairing with an FDA approval, and that approval is narrow.
- Approved use: reduction of excess visceral abdominal fat in HIV-positive adults with lipodystrophy.
- Typical prescribed dose: 1.4 mg or 2 mg injected subcutaneously once daily, depending on the formulation.
- Common side effects: injection-site reactions, joint pain, muscle pain, and peripheral swelling.
- Serious considerations: tesamorelin can worsen glucose tolerance and is contraindicated with active malignancy or pregnancy.
Tesamorelin is not approved for general weight loss, and it is a prescription-only medicine in the United States that requires IGF-1 and blood sugar monitoring.
What Is AOD 9604?
AOD 9604 is a modified piece of human growth hormone, corresponding to amino acids 176-191 of the HGH molecule. It was designed to keep the fat-burning region of growth hormone while removing the parts linked to blood sugar spikes and tissue growth.
Early animal and laboratory studies suggested it could break down fat without raising blood glucose or IGF-1. Human results have been far less impressive.
- Approval status: AOD 9604 is not FDA-approved for any human indication.
- Human trials: a large Phase IIb obesity trial did not meet its primary weight-loss endpoint, although the compound has also been studied for osteoarthritis and metabolic markers.
- How it is sold: as a research chemical labeled "not for human consumption."
- Athlete status: banned by WADA as a non-approved substance.
Because AOD 9604 is unapproved, products sold online vary widely in purity and actual content, and published dosing comes from research literature rather than prescribing guidelines.
Tesamorelin vs AOD 9604: Side-by-Side Comparison
The two compounds differ on nearly every practical measure, from mechanism to regulatory status.
| Feature | Tesamorelin | AOD 9604 |
|---|---|---|
| Compound type | GHRH analog (44 amino acids) | HGH fragment 176-191 |
| Mechanism | Stimulates pituitary growth hormone release; raises IGF-1 | Direct lipolytic activity on fat cells; does not raise IGF-1 in studies |
| FDA status | Approved for HIV-associated lipodystrophy | Not approved for any human use |
| Human evidence | Randomized trials show visceral fat reduction | Phase IIb obesity trial failed its primary endpoint |
| Route studied | Subcutaneous injection | Oral and subcutaneous in early research |
| Common side effects | Injection-site reactions, joint pain, swelling, glucose changes | Limited human safety data |
| How it is obtained | Prescription only | Research chemical market |
Can You Stack AOD 9604 With Tesamorelin?
Some people research using aod 9604 with tesamorelin in the same protocol, hoping to combine a prescription GHRH analog with a non-approved HGH fragment. No controlled human trial has tested that combination, so any claim about synergy is speculation rather than evidence.
The aod-9604 mots-c tesamorelin stack adds a third unapproved peptide, MOTS-c, into the mix. Stacking multiple research compounds multiplies unknown variables — overlapping side effects, unknown interactions, and no safety data — without adding proven benefit.
If you are choosing between tesamorelin or aod 9604, the decision usually comes down to goals, medical supervision, and legal access. Tesamorelin requires a prescription and lab monitoring; AOD 9604 has no approved human dose at all.
Dosage and Research Considerations
Any aod-9604 mots-c tesamorelin dosage you find online is extrapolated from animal studies, single-compound human trials, or personal anecdotes. No published trial has established a safe or effective dose for these three peptides used together.
- Tesamorelin dosing comes from FDA labeling: 1.4 mg or 2 mg subcutaneously once daily for the approved indication.
- AOD 9604 doses circulating in forums are copied from early research that never produced a successful Phase III program.
- MOTS-c remains an experimental mitochondrial peptide with no approved human dosing.
- More compounds in a syringe does not mean more benefit; it usually means more risk and harder-to-interpret lab results.
Safety, Sourcing, and Legal Status
Tesamorelin is legal only by prescription in the United States, and it is dispensed with monitoring for IGF-1, glucose, and injection-site problems. AOD 9604 is not approved for human use, which means no pharmacy oversight, no guaranteed purity, and no dosing standard.
Unapproved peptides sold online have been found in independent testing to contain incorrect amounts of active ingredient, endotoxins, or entirely different compounds. Anyone considering either peptide should talk with a licensed healthcare professional rather than rely on vendor claims or forum posts.
Neither tesamorelin nor AOD 9604 is a substitute for diet, exercise, or FDA-approved weight-management treatments.
The Bottom Line
Tesamorelin is a narrowly approved prescription peptide with real clinical trial data behind it, and AOD 9604 is an unapproved HGH fragment whose largest human trial missed its weight-loss goal. AOD 9604 and tesamorelin are not interchangeable, and no evidence supports stacking them together with MOTS-c.
If fat loss is your goal, the safest path runs through a clinician who can review your history, order labs, and discuss options that are actually approved for human use.
Frequently Asked Questions
Is AOD 9604 the same as tesamorelin?
No. Tesamorelin is a GHRH analog that raises growth hormone and IGF-1, and it is FDA-approved for visceral fat in HIV-associated lipodystrophy. AOD 9604 is a fragment of human growth hormone (amino acids 176-191) that is not FDA-approved for any human use. They have different mechanisms, different evidence, and different legal status.
Is AOD 9604 FDA-approved for weight loss?
No. AOD 9604 has never been approved by the FDA for weight loss or any other human indication. A large Phase IIb obesity trial did not meet its primary weight-loss endpoint, and the peptide is sold as a research chemical labeled not for human consumption.
Can AOD 9604 and tesamorelin be stacked?
There is no human trial testing AOD 9604 and tesamorelin together, so the combination is unstudied and unproven. Adding a third research peptide such as MOTS-c increases the number of unknown interactions and side effects. Anyone considering these compounds should consult a licensed healthcare professional first.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.